Peripheral Artery Disease
Registry to better guide CLTI care; 1 in 6 patients die within first year of diagnosis
Among 1.13 million patients with chronic limb-threatening ischemia and long-term follow-up, approximately one in six died within their first year of diagnosis, a rate that increased to half by 5 years, a speaker reported.
Intravascular lithotripsy catheter to treat calcified peripheral lesions launched
Shockwave Medical announced that its intravascular lithotripsy catheter for treatment of calcified peripheral artery lesions has been launched commercially in the United States.
Amid pandemic, elective CVD admissions down, ED visits up in UK
In the U.K., the severity of CVD comorbidities increased during the pandemic while elective admissions and procedures decreased, an observation accompanied by increased emergency admissions, researchers reported.
Food insecurity raises risk for poor outcomes in patients with PAD
CHICAGO — Among patients with peripheral artery disease, those with food insecurity had elevated risk for a major CV event, researchers reported at the American Heart Association Scientific Sessions.
Intravascular lithotripsy improves stenosis in real-world cohort of calcified PAD
In a real-world observational study, intravascular lithotripsy was associated with improvement in stenosis in patients with calcified peripheral artery disease, researchers reported at VIVA 22.
Novel DCB noninferior to standard-of-care DCB at 24 months
A novel low-dose paclitaxel-coated balloon was noninferior to a higher-dose paclitaxel-coated balloon at 24 months in patients with peripheral artery disease, according to new data from the TRANSCEND trial.
DCBs may be superior to bare-metal stents in patients with femoropopliteal artery disease
In patients with femoropopliteal artery disease amenable to treatment with drug-coated balloons or bare-metal stents, DCBs appear to be the better option, according to an analysis presented at VIVA 22.
Lp(a) ‘should be measured at least once’ in adults to target CV risk
BOSTON — There is strong evidence for a casual association between lipoprotein(a) concentration and CV outcomes across ethnicities, and Lp(a) “should be measured at least once” in all adults to identify high CV risk, according to a speaker.
AHA statement: PAD treatment must focus on patient-reported symptoms, quality of life
Patient-reported outcome measures that assess a range of relevant domains such as health status and quality of life are vital for the comprehensive management of peripheral artery disease, according to a new scientific statement.
Atherectomy system gains new indication for arterial thrombectomy
AngioDynamics announced it received an FDA clearance of an expanded indication for its atherectomy system to include arterial thrombectomy.